Alfonso Piciocchi | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT	BLOOD TRANSFUSION	2025
Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients	EJHAEM	2024
Impact of Daratumumab on Stem Cell Mobilization and Transplant in Patient with Newly Diagnosed Multiple Myeloma: A Real Word Single-Centre Study	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial	LEUKEMIA	2024
Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years	CANCERS	2024
HODGKIN LYMPHOMA IN CHILDREN: A 16-YEAR EXPERIENCE AT THE CHILDREN’S WELFARE TEACHING HOSPITAL OF BAGHDAD, IRAQ	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2024
Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study	HAEMATOLOGICA	2024
Impact analysis of SARS-CoV-2 vaccination in patients treated with monoclonal antibodies. A monocentric experience	INTERNATIONAL IMMUNOPHARMACOLOGY	2024
Health-Related Quality of Life and Financial Burden in Ethiopian Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Study	JCO GLOBAL ONCOLOGY	2024
Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia	BLOOD	2024
Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian cooperative analysis	JOURNAL OF CLINICAL ONCOLOGY	2023
Pseudo-observations in survival analysis	Book of short papers SIS 2023	2023
S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY	HEMASPHERE	2023
P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE	HEMASPHERE	2023
P523: The comparison of VFLAI, FLAI and 3 + 7 regimens by multilevel propensity score weighting highlights the benefit of the addition of venetoclax in no low risk aml treated in Gimema trials real world	HEMASPHERE	2023
P499: APPLICABILITY OF 2022 CLASSIFICATIONS OF ACUTE MYELOID LEUKEMIA IN THE REAL-WORLD SETTING	HEMASPHERE	2023
Donor specific anti-HLA antibodies in hematopoietic stem cell transplantation. Single Center prospective evaluation and desensitization strategies employed	BLOOD TRANSFUSION	2023
Unraveling the Impact of 2022 Classifications on Secondary Acute Myeloid Leukemia: Assessing the True Qualification Power of Diagnostic Qualifiers	BLOOD	2023
Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: An Italian Monocentric Experience	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2023
Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia	BLOOD	2023